HK Stock Market Move | PEGBIO CO-B(02565) high opens by over 7%, cornerstone investors voluntarily extend lock-up period.

PEGBIO CO-B(02565) opened more than 7% higher, rising 7.03% to HK$70 as of the time of writing, with a turnover of HK$770,000. On the news front, on the evening of November 26, Pegbio Biopharmaceuticals announced that it had recently received notification from Benefactor Kanging Pharmaceutical (Hong Kong) Limited (cornerstone investor) that the cornerstone investor agreed not to reduce its holdings in any related H shares in any way from the original expiration date of the lock-up period to December 31, 2025 (extension of lock-up period). The company believes that the extension of the lock-up period indicates that the cornerstone investor is confident in the company's future prospects based on the company's research and development capabilities in advancing technology and the significant progress made in key clinical milestones. It is worth mentioning that Pegbio Biopharmaceuticals recently announced that the National Medical Products Administration has approved the new drug market application for the company's core product, PB-119. Softbank China Research Report pointed out that based on the clinical advantages of PB-119 in T2DM and weight reduction indications, combined with the pipeline potential of PB-718 and others, rapid revenue growth is expected from 2026 to 2029. DCF valuation shows that the company has significant upside potential, with outstanding safety and long-acting properties of core products, especially suitable for elderly diabetic patients, with the best potential among similar products.